Union Korea Pharm

At a glance

Union Korea Pharm filed 95 disclosures in the last 12 months, including 5 issuance, 3 5% holder and 2 insider. The most recent key filing was on Oct 21: Capital reduction of 0.3%.

Revenue for 2025 was ₩36.4B, down 29.1% on 2024. It made an operating loss of ₩17.2B. Debt was -300% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩11.8B and operating loss of ₩2.8B.

The 2025 annual report lists 123 employees with an average tenure of 4.3 years and average pay of ₩39.2M, #2101 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩37M each on average. It paid no cash dividend for 2025. 멜빈에프앤비 and related parties held 19.93% at year end.

Of 3 recent 5%+ holder reports, 2 raised and 1 cut a stake; the largest stake reported was 75.14% on Jun 4.

From the 2025 annual report

Staff: 123 (70 men, 53 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.8B. Directors and auditors: 8, paid ₩295M in total.

No cash dividend was paid for 2025.

Largest shareholder

멜빈에프앤비 holds 19.93%; with 0 related parties the group holds 19.93% of common shares at year end (from 0.00% at the start of the year).

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports